Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model

Prostate

Volumn 73, Issue 9, 2013, Pages 913-922

  Kobayashi, Daichi ^a   Kawai, Noriyasu ^a   Sato, Shinya ^a   Naiki, Taku ^a   Yamada, Kenji ^a   Yasui, Takahiro ^a   Tozawa, Keiichi ^a   Kobayashi, Takeshi ^b   Takahashi, Satoru ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b CHUBU UNIVERSITY   (Japan)

Author keywords

bone metastasis; cell death; combination therapy; docetaxel; magnetic cationic liposomes; osteoclasts

Indexed keywords

CD86 ANTIGEN; DOCETAXEL; HEAT SHOCK PROTEIN 70; LIPOSOME; MAGNETIC CATIONIC LIPOSOME; UNCLASSIFIED DRUG;

ALTERNATING MAGNETIC FIELD IRRADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BONE NECROSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMUR; HYPERTHERMIC THERAPY; IRRADIATION; LYMPHOCYTE COUNT; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; BONE NEOPLASMS; CATIONS; COLLOIDS; DISEASE MODELS, ANIMAL; FERUMOXYTOL; HYPERTHERMIA, INDUCED; LIPOSOMES; MAGNETICS; MALE; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RATS; RATS, INBRED F344; TAXOIDS;

EID: 84878343347     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22637     Document Type: Article

References (41)

1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ,. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583.
2. Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ,. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011; 17: 3924-3932.
3. Saad F, Clarke N, Colombel M,. Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006; 49: 429-440.
4. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
5. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA,. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6: 2609-2617.
6. Kozlow W, Guise TA,. Breast cancer metastasis to bone: Mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10: 169-180.
7. Yoneda T, Hiraga T,. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005; 328: 679-687.
8. Finkelman RD, Mohan S, Jennings JC, Taylor AK, Jepsen S, Baylink DJ,. Quantitation of growth factors IGF-I, SGF/IGF-II, and TGF-beta in human dentin. J Bone Miner Res 1990; 5: 717-723.
9. Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T,. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci 2008; 99: 316-323.
10. Solheim E,. Growth factors in bone. Int Orthop 1998; 22: 410-416.
11. Berry S, Waldron T, Winquist E, Lukka H,. The use of bisphosphonates in men with hormone-refractory prostate cancer: A systematic review of randomized trials. Can J Urol 2006; 13: 3180-3188.
12. Saad F, McKiernan J, Eastham J,. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 2006; 24: 4-12.
13. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C,. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011; 377: 813-822.
14. Kusaka M, Takegami K, Sudo A, Yamazaki T, Kawamura J, Uchida A,. Effect of hyperthermia by magnetite cement on tumor-induced bone destruction. J Orthop Sci 2002; 7: 354-357.
15. Abe M, Hiraoka M, Takahashi M, Egawa S, Matsuda C, Onoyama Y, Morita K, Kakehi M, Sugahara T,. Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for cancer therapy. Cancer 1986; 58: 1589-1595.
16. Kawai N, Futakuchi M, Yoshida T, Ito A, Sato S, Naiki T, Honda H, Shirai T, Kohri K,. Effect of heat therapy using magnetic nanoparticles conjugated with cationic liposomes on prostate tumor in bone. Prostate 2008; 68: 784-792.
17. Kawai N, Ito A, Nakahara Y, Futakuchi M, Shirai T, Honda H, Kobayashi T, Kohri K,. Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate 2005; 64: 373-381.
18. Kawai N, Ito A, Nakahara Y, Honda H, Kobayashi T, Futakuchi M, Shirai T, Tozawa K, Kohri K,. Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core. Prostate 2006; 66: 718-727.
19. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T,. Intracellular hyperthermia for cancer using magnetite cationic liposomes: An in vivo study. Jpn J Cancer Res 1998; 89: 463-469.
20. Shirai T, Tamano S, Kato T, Iwasaki S, Takahashi S, Ito N,. Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,2'-dimethyl-4-aminobiphenyl and testosterone propionate. Cancer Res 1991; 51: 1264-1269.
21. Sato S, Takahashi S, Asamoto M, Naiki T, Naiki-Ito A, Asai K, Shirai T,. Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro. Prostate 2010; 70: 229-238.
22. Owen CS, Sykes NL,. Magnetic labeling and cell sorting. J Immunol Methods 1984; 73: 41-48.
23. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T,. Intracellular hyperthermia for cancer using magnetite cationic liposomes: In vitro study. Jpn J Cancer Res 1996; 87: 1179-1183.
24. Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, Lewis RF, Harris GJ, Lev M, Schaefer PW, Buchbinder BR, Barest G, Yamada K, Ponzo J, Kwon HY, Gemmete J, Farkas J, Tievsky AL, Ziegler RB, Salhus MR, Weisskoff R,. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001; 19: 551-557.
25. Jensen MM, Jorgensen JT, Binderup T, Kjaer A,. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008; 8: 16.
26. Mundy GR,. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
27. Fu X, Herrea H, Hoffman RM,. Orthotopic growth and metastasis of human prostate carcinoma in nude mice after transplantation of histologically intact tissue. Int J Cancer 1992; 52: 987-990.
28. Hoffman RM,. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic. Invest New Drugs 1999; 17: 343-359.
29. Yang M, Jiang P, Yamamoto N, Li L, Geller J, Moossa AR, Hoffman RM,. Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein. Prostate 2005; 62: 374-379.
30. Hoffman RM,. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5: 796-806.
31. Hoffman RM, Yang M,. Whole-body imaging with fluorescent proteins. Nat Protoc 2006; 1: 1429-1438.
32. Mukhopadhaya A, Mendecki J, Dong X, Liu L, Kalnicki S, Garg M, Alfieri A, Guha C,. Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res 2007; 67: 7798-7806.
33. Ito A, Shinkai M, Honda H, Yoshikawa K, Saga S, Wakabayashi T, Yoshida J, Kobayashi T,. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003; 52: 80-88.
34. Radons J, Multhoff G,. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc Immunol Rev 2005; 11: 17-33.
35. Udono H, Levey DL, Srivastava PK,. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: Tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 1994; 91: 3077-3081.
36. Suto R, Srivastava PK,. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269: 1585-1588.
37. Subjeck JR, Sciandra JJ, Chao CF, Johnson RJ,. Heat shock proteins and biological response to hyperthermia. Br J Cancer Suppl 1982; 5: 127-131.
38. Subjeck JR, Sciandra JJ, Johnson RJ,. Heat shock proteins and thermotolerance; A comparison of induction kinetics. Br J Radiol 1982; 55: 579-584.
39. Lindquist S,. The heat-shock response. Annu Rev Biochem 1986; 55: 1151-1191.
40. Horowitz M, Robinson SD,. Heat shock proteins and the heat shock response during hyperthermia and its modulation by altered physiological conditions. Prog Brain Res 2007; 162: 433-446.
41. Wonganan P, Zamboni WC, Strychor S, Dekker JD, Croyle MA,. Drug-virus interaction: Effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Cancer Gene Ther 2009; 16: 405-414.